Clinical trial
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee…
NCT00475800 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00475800 |
|---|---|
| Title | Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA) |
| Official title | A 39-week, Open-label Extension to CCOX189A2360, a 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee… |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis |
| Intervention type | Drug |
| Interventions | Lumiracoxib |
| Enrollment | 833 |
| Start date | Jan 1, 2004 |
| Primary completion | Dec 1, 2004 |
| First posted | May 21, 2007 |
| Last update posted | May 21, 2012 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: